cannabidiol - Profile

What are the generic sources for cannabidiol and what is the scope of patent protection?

Cannabidiol is the generic ingredient in one branded drug marketed by Jazz Pharms Res and is included in one NDA. There are thirty-two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cannabidiol has one hundred and seventy-two patent family members in twenty-seven countries.

Summary for cannabidiol

International Patents:	172
US Patents:	32
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for cannabidiol

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for cannabidiol

Constraining patent/regulatory exclusivity:

TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS BETWEEN 1 AND 2 YEARS OF AGE

Dosage:

SOLUTION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for CANNABIDIOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPIDIOLEX	Oral Solution	cannabidiol	100 mg/mL	210365	10	2022-09-28

US Patents and Regulatory Information for cannabidiol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes

Expired US Patents for cannabidiol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018

EU/EMA Drug Approvals for cannabidiol

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Jazz Pharmaceuticals Ireland Limited	Epidyolex	cannabidiol	EMEA/H/C/004675Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.	Authorised	no	no	yes	2019-09-19

International Patents for cannabidiol

Country	Patent Number	Title	Estimated Expiration
Japan	2021522261
World Intellectual Property Organization (WIPO)	2016203239
Denmark	3784283
Australia	2024204928	Use of cannabidiols in the treatment of epilepsy

Investment Scenario and Fundamentals Analysis for Cannabidiol (CBD)

Last updated: February 20, 2026

What Is the Current Market and Regulatory Environment for CBD?

The global cannabidiol (CBD) market is expanding rapidly, driven by increasing interest in cannabis-derived products for health and wellness. The market was valued at approximately USD 4.6 billion in 2022 and is projected to reach USD 17.8 billion by 2028, growing at a CAGR of around 28% (Grand View Research, 2022).

Regulations vary significantly across regions. In the U.S., the 2018 Farm Bill legalized hemp-derived CBD containing less than 0.3% THC, enabling wide commercialization. The FDA has yet to establish clear regulations for dietary supplements and health claims related to CBD. In Europe, regulatory frameworks are stricter, often requiring novel food authorizations before market entry.

What Are the Key R&D and Patent Considerations?

CBD's pharmacological profile includes potential therapeutic effects such as anti-inflammatory, anxiolytic, anticonvulsant, and neuroprotective actions. Clinical evidence remains limited but promising. Patents related to formulations, delivery methods, and specific therapeutic uses form the basis for competitive advantage.

Major pharmaceutical players have filed patents on cannabinoid formulations:

• GW Pharmaceuticals holds patents (e.g., US patent US9458478B2) covering cannabinoid formulations for epilepsy.
• CJ CheilJedang and other biotech firms focus on novel delivery systems, such as transdermal patches and nanocarriers.
• Patents typically have a 20-year term from filing; many filed around 2010-2015, meaning exclusivity could extend into the early 2030s.

Patent diversity exists in synthetic CBD compounds versus botanical extracts, influencing development pathways.

What Are the Commercial and Clinical Development Statuses?

Several companies are advancing CBD-based therapeutics:

• Epidiolex (GW Pharmaceuticals/Spectrum Pharmaceuticals) is FDA-approved for Lennox-Gastaut and Dravet syndromes. Sales reached USD 450 million in 2022.
• Clinical trials are ongoing for CBD in conditions including multiple sclerosis (MS), schizophrenia, and anxiety. Many are phase 2 or 3, but no comprehensive regulatory approvals exist outside epilepsy.

Investors should consider:

• Market exclusivity periods for key formulations.
• The pipeline risk of future clinical failures.
• Commercial scale-up challenges, including sourcing and standardization of CBD extracts.

What Are the Fundamentals for Investment?

• Market growth: Driven by consumer demand, medical research, and regulatory progress.
• Patent portfolios: Firm-specific, with companies holding exclusive rights to certain formulations.
• Regulatory risk: Changes to laws can either expand or restrict market access.
• Clinical validation: The transition from regulatory approval to actual therapeutic efficacy remains uncertain.
• Supply chain: Reliance on cultivated hemp and extraction processes affects cost and quality control.

Major investment considerations include evaluation of R&D spending, patent expiration timelines, and regional regulatory shifts.

How Do Competitive Dynamics Shape the Investment Outlook?

The market has a mix of large pharmaceutical firms, biotech startups, and nutraceutical companies. Key players with intellectual property and clinical trial progress hold competitive advantages. Entry barriers include the high cost of R&D and regulatory compliance.

New entrants face challenges in establishing patents or gaining market share. Patent expirations starting around 2030 could open opportunities for generics or biosimilar-like entrants.

What Are the Main Risks and Opportunities?

Risks:

• Regulatory restrictions or delays.
• Clinical trial failures or inconsistent efficacy data.
• Supply chain disruptions affecting quality and cost.
• Legal challenges to patents or market access.

Opportunities:

• Expanding indications beyond epilepsy.
• Advancements in delivery technology.
• Growing consumer markets for wellness products.
• Potential for early entry into markets with emerging regulations.

Key Takeaways

• The CBD market is expanding rapidly with significant growth potential but limited regulatory clarity outside specific indications like epilepsy.
• Patent exclusivity is critical; most key assets are protected into the early 2030s.
• Clinical development progress is promising but still uncertain for therapeutic applications beyond epilepsy.
• Regulatory and supply chain risks require careful monitoring.
• Competitive advantage depends heavily on intellectual property, clinical validation, and strategic regional regulations.

FAQs

1. What are the main patent challenges facing CBD therapeutics?
Most patents cover specific formulations, delivery methods, or therapeutic indications. Patent expiry around 2030-2035 creates opportunities for generics.

2. How does FDA regulation impact investment in CBD-based drugs?
FDA approval is limited mainly to epilepsy (Epidiolex). Broader therapeutic approvals face uncertain regulatory pathways, influencing potential market size.

3. What is the outlook for non-therapeutic CBD products?
CBD in wellness and dietary supplements faces fewer regulatory hurdles but lacks clinical validation. Market growth depends on consumer demand and regulatory acceptance.

4. Are there supply chain risks for CBD production?
Yes. Cultivation quality, extraction efficiency, and standardization influence product quality and cost, affecting profitability.

5. How does regional regulation influence the global market?
Legal frameworks significantly impact market access. North America and parts of Europe are leading markets, while Asia-Pacific remains less developed due to stricter legal environments.

---

References

[1] Grand View Research. (2022). Cannabidiol (CBD) Market Size, Share & Trends Analysis Report.

[2] U.S. Food and Drug Administration. (2020). FDA and Cannabis: Research, Drug Approval, and Regulations.

[3] Patent databases (e.g., USPTO, EPO).

[4] ClinicalTrials.gov. (2023). CBD-related Clinical Trials Data.